- Home
- BIIB vs VOD Comparison
BIIB vs VOD Comparison
Compare BIIB & VOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- VOD
- Stock Information
- Founded
- BIIB 1978
- VOD 1984
- Country
- BIIB United States
- VOD United Kingdom
- Employees
- BIIB N/A
- VOD N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- VOD Telecommunications Equipment
- Sector
- BIIB Health Care
- VOD Telecommunications
- Exchange
- BIIB Nasdaq
- VOD Nasdaq
- Market Cap
- BIIB 25.1B
- VOD 22.6B
- IPO Year
- BIIB 1991
- VOD 1988
- Fundamental
- Price
- BIIB $164.23
- VOD $8.87
- Analyst Decision
- BIIB Buy
- VOD
- Analyst Count
- BIIB 25
- VOD 0
- Target Price
- BIIB $258.57
- VOD N/A
- AVG Volume (30 Days)
- BIIB 1.7M
- VOD 6.4M
- Earning Date
- BIIB 10-30-2024
- VOD 11-12-2024
- Dividend Yield
- BIIB N/A
- VOD 8.00%
- EPS Growth
- BIIB 10.05
- VOD N/A
- EPS
- BIIB 11.06
- VOD 0.11
- Revenue
- BIIB $9,607,500,000.00
- VOD $41,278,161,929.00
- Revenue This Year
- BIIB N/A
- VOD $6.34
- Revenue Next Year
- BIIB N/A
- VOD $1.74
- P/E Ratio
- BIIB $14.85
- VOD $8.15
- Revenue Growth
- BIIB N/A
- VOD 5.15
- 52 Week Low
- BIIB $153.62
- VOD $8.02
- 52 Week High
- BIIB $268.30
- VOD $10.39
- Technical
- Relative Strength Index (RSI)
- BIIB 42.84
- VOD 42.15
- Support Level
- BIIB $158.44
- VOD $8.84
- Resistance Level
- BIIB $160.63
- VOD $9.03
- Average True Range (ATR)
- BIIB 4.14
- VOD 0.13
- MACD
- BIIB 0.94
- VOD 0.03
- Stochastic Oscillator
- BIIB 47.71
- VOD 73.33
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About VOD Vodafone Group Plc
Vodafone operates mobile and fixed-line networks and businesses in more than 20 countries. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns a cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK it acts as a mobile operator and is attempting a merger with CK Hutchison as of 2024. In 2024 Vodafone also divested its Spanish and Italian divisions, given their low returns on invested capital.